期刊文献+

Preparation of thalidomide nano-flakes by supercritical antisolvent with enhanced mass transfer 被引量:5

Preparation of thalidomide nano-flakes by supercritical antisolvent with enhanced mass transfer
原文传递
导出
摘要 Thalidomide treats multiple myeloma and protracts life-span of patient, but its bioavailability is limited as it is poorly water soluble. Thalidomide nano-flakes are produced to improve the drug dissolution rate. Two nanoflake production methods are utilized for a comparative study: a supercritical antisolvent (SAS) method and a supercritical antisolvent with enhanced mass transfer (SAS-EM). SAS-EM utilizes ultrasonication to improve dispersion upon injection within the supercritical carbon dioxide. Comparative study of SAS and SAS-EM thalidomide confirmed that the application of ultrasonication improved the micro/nano particles produced by SAS. The effects of ultrasound power on the formation of thalidomide particles are examined. The particle size and morphology were characterized by SEM. The thalidomide nano-flakes produced by SAS-EM were smaller than the particles produced by SAS. Dissolution rates of the produced particles, evaluated by HPLC, demonstrated an increase in the thalidomide dissolution rate for the SAS-EM produced particles, The polymorphs and crystallinity of thalidomide particles (flakes) were observed by FTIR and XRD. In this research, the supercritical processing significantly modified the crystal formation of thalidomide from an original state of a β-polymorph to the amorphous state α-polymorph after suoercritical orocessing. Thalidomide treats multiple myeloma and protracts life-span of patient, but its bioavailability is limited as it is poorly water soluble. Thalidomide nano-flakes are produced to improve the drug dissolution rate. Two nanoflake production methods are utilized for a comparative study: a supercritical antisolvent (SAS) method and a supercritical antisolvent with enhanced mass transfer (SAS-EM). SAS-EM utilizes ultrasonication to improve dispersion upon injection within the supercritical carbon dioxide. Comparative study of SAS and SAS-EM thalidomide confirmed that the application of ultrasonication improved the micro/nano particles produced by SAS. The effects of ultrasound power on the formation of thalidomide particles are examined. The particle size and morphology were characterized by SEM. The thalidomide nano-flakes produced by SAS-EM were smaller than the particles produced by SAS. Dissolution rates of the produced particles, evaluated by HPLC, demonstrated an increase in the thalidomide dissolution rate for the SAS-EM produced particles, The polymorphs and crystallinity of thalidomide particles (flakes) were observed by FTIR and XRD. In this research, the supercritical processing significantly modified the crystal formation of thalidomide from an original state of a β-polymorph to the amorphous state α-polymorph after suoercritical orocessing.
出处 《Particuology》 SCIE EI CAS CSCD 2012年第1期17-23,共7页 颗粒学报(英文版)
基金 supported by the National 863 Programme Foundation from the Ministry of Science and Technology of the People's Republic of China(2007AA10Z350) the National Natural Science Foundation of China(20976103)
关键词 Supercritical Anti-solventUltrasound THALIDOMIDE Nano-flakes Polymorph SupercriticalAnti-solventUltrasoundThalidomideNano-flakesPolymorph
  • 相关文献

参考文献35

  • 1Bahrami, M. & Ranjbarian, S. (2007). Production of micro-and nano-composite particles by supercritical carbon dioxide.Journal of Supercritical Fluids, 40, 263-283.
  • 2Beach, S., Latham, D., Sidgwick, C., Hanna, M. & York, P. (1999). Control of the physical form of salmeterol xinafoate. Organic Process Research and Development, 3, 370-376.
  • 3Bensinger, W. (2007). Initial therapy of multiple myeloma in patients who are candidates for stem cell transplantation. Current Treatment Options in Oncology, 8(2), 135-143.
  • 4Bleich, J., Kleinebudde, P. & Mueller, B. W. (1994). Influence of gas density and pressure on microparticles produced with the ASES process. International Journal of Pharmaceutics, 106(1 ), 77-84.
  • 5Caira, M. R., Botha, S. A. & Flanagan, D. R. (1994). Polymorphism of n-(2,6-dioxo- 3-piperidyl)phthalimide(thalidomide)-Structural characterization of a second monoclinic racemic modification. The Journal of Chemical Crystallography, 24, 95-99.
  • 6Candoni, A., Raza, A., Galili, N., Simeone, E., Buttignol, S., Silvestri, F., et al. (2007). Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS). Leukemia Research, 31(Suppl. 1 ), 119.
  • 7Carini, J. P., Pavei, C., Silva, A. P. C., Machado, G., Mexias, A. S., Pereira, V. P., et al. (2009). Solid state evaluation of some thalidomide raw materials. International Journal of Pharmaceutics, 372, 17-23.
  • 8Chattopadhyay, P. & Gupta, R. B. (2001). Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer. International Journal of Pharmaceutics, 228, 19-31.
  • 9Chattopadhyay, P. & Gupta, R. B. (2002). Protein nanoparticles formation by supercritical antisolvent with enhanced mass transfer. AIChEJoumal, 48, 235-244.
  • 10Cipriani, P. & Smith, C. Y. (2007). Characterization of thalidomide using Raman spectroscopy. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 69(2), 333-337.

同被引文献17

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部